Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan

Advanced technology supports drug development across diseases including cancer and cerebrovascular disease

BURLINGTON, N.C., May 16, 2023 — Labcorp (NYSE: LH), a leading global life sciences company, broke ground on a the expansion project of its CB Trial Laboratory in a ceremony held at the construction site near the BML Research Institute and General Laboratory in Kawagoe City on April 28, 2023. The new facility enhances the company’s central laboratory presence and drug development capabilities in Japan allowing greater focus on serving the unique healthcare needs affecting people in the region and leveraging technology to expand testing capabilities. Completion of the expanded laboratory is expected by early 2025 and will provide more than 4,000 square meters of additional dedicated space to support global clinical trials managed by Labcorp.

This facility, when complete, will provide Labcorp and BML pharmaceutical and biotechnology clients with enhanced access to central laboratory testing and drug development capabilities. It will deliver a unique set of services to meet the specific needs of the population in Japan, including white glove courier service, and will focus attention on the health conditions that disproportionately affect Japanese citizens, including gastric cancer and cerebrovascular disease. Additionally, Labcorp will provide technological capabilities that will enable BML to significantly expand its specialty testing capabilities in the areas of  genomics, anatomic pathology and histology, as well as the opportunity to partner on emerging companion diagnostics focused on oncology.
 
Completion of the expanded laboratory is expected by early 2025 and will provide more than 4,000 square meters of additional dedicated space to support global clinical trials managed by Labcorp.
CB Trial Laboratory, which is co-managed by Labcorp and BML, is a leading provider of clinical laboratory testing services in Japan. Under the sponsorship of the construction company, and with the cooperation of Ozaki Shrine, BML and Labcorp executives led the audience in prayer, seeking the safety and security of the construction.

To learn more about Labcorp’s operations in Japan, please click here.
 

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 80,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.9 billion in FY2022. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Labcorp Contacts: Media: Kim Arculeo - 336-436-8263, [email protected]; Investors: Chas Cook -- 336-436-5076, [email protected]